Showing results (391-400 of 405) with videos related to
Sort By:
Pageof 41
Journal of Bacteriology|July 27, 2002
Genome sequence of Yersinia pestis KIMWen Deng, Valerie Burland, Guy Plunkett, et al.Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.ACS Medicinal Chemistry Letters|February 20, 2020
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaZenon Konteatis, Erin Artin, Brandon Nicolay, et al.Nature|July 22, 2014
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerSupriya K Saha, Christine A Parachoniak, Krishna S Ghanta, et al.Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.Neuro-Oncology|December 23, 2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Robert J Young, Jennifer Rubel, et al.Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.Pageof 41